今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

阿里影业强劲反弹 午后涨超4% 年度收入同比增长44%

北京 - 阿里影业（01060）在周五午后的交易中强劲反弹，涨幅超过4%，收报0.46港元。该股当日成交额2497.01万港元。

此轮上涨主要得益于阿里影业近日发布的2024财年业绩公告。公告显示，公司该财年收入同比增长44%，至人民币325亿元，净利润同比增长64%，至人民币62亿元。

强劲的财务表现反映了中国电影和演出行业的蓬勃发展。得益于疫情防控措施的放松和居民消费能力的回升，中国电影市场在过去一年中呈现强劲复苏态势。2023年中国电影票房同比增长46%，达到1200亿元人民币。

阿里影业作为中国电影行业的龙头企业，充分受益于行业发展红利。公司在电影制作、发行、放映等多个环节拥有领先优势，并积极布局线上业务，打造多元化业务体系。

在电影制作方面，阿里影业投资制作了多部票房成功影片，包括《你好，李焕英》、《长津湖》等。在电影发行方面，公司拥有强大的发行渠道和资源，能够有效地将优质影片推向市场。在电影放映方面，公司旗下猫眼娱乐是国内领先的电影票务平台，拥有庞大的用户基群。

此外，阿里影业还积极布局线上业务，发展流媒体、衍生品等业务。公司旗下的优酷视频是国内领先的视频平台，拥有丰富的影视内容资源。

阿里影业表示，将继续深耕电影主业，并积极布局线上业务，努力为股东创造更大的价值。

分析人士认为，阿里影业未来发展前景依然看好。随着中国电影行业的持续发展和公司业务结构的不断优化，阿里影业有望实现业绩的进一步增长。